A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure (AUGMENT-HF)
A Randomized, Controlled Study to Evaluate the Safety and Cardiovascular Effects of Algisyl-LVR™ as a Method of Left Ventricular Augmentation in Patients With Dilated Cardiomyopathy (AUGMENT-HF)
Sponsor: LoneStar Heart, Inc.
Listed as NCT01311791, this PHASE2/PHASE3 trial focuses on Dilated Cardiomyopathy and Heart Failure and remains completed. Sponsored by LoneStar Heart, Inc., it has been updated 8 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 3 earlier versions
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LoneStar Heart, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auckland, New Zealand , Bergamo, Italy , Berlin, Germany , Bucharest, Romania , Cremona, Italy , Dresden, Germany , Kiel, Germany , Melbourne, Australia , Milan, Italy , Nieuwegein, Netherlands and 4 more locations